Zydus Cadila has received the tentative approval from the US FDA to market abacavir and lamivudine tablets USP, 600 mg/300 mg. The drug is indicated for use in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

According to IMS Health, IMS National Sales Perspective Audit, MAT June 2017, the sales of abacavir and lamivudine tablets is estimated at $240.2 million.

The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.